INCY Incyte Corporation

By Colin Kellaher

Eli Lilly & Co. and Incyte Corp. on Wednesday said the U.S. Food and Drug Administration granted full approval for the use of their arthritis drug Olumiant for the treatment of certain hospitalized patients with Covid-19.

The companies said the approval covers hospitalized adults needing supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation, with a recommended dose of four milligrams a day for 14 days or until discharge.

Eli Lilly and Incyte said the FDA nod makes Olumiant the first and only Janus kinase, or JAK, inhibitor cleared for the treatment of Covid-19 in hospitalized adults needing various degrees of oxygen support.

The FDA granted emergency-use authorization for Olumiant in November 2020. That authorization will remain in place for hospitalized pediatric patients ages 2 through 18, the company said.

Indianapolis-based Eli Lilly signed an exclusive world-wide license and collaboration agreement with Incyte, a Wilmington, Del., biopharmaceutical company, in late 2009 to develop and commercialize Olumiant and other compounds for inflammatory and autoimmune diseases.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 11, 2022 07:28 ET (11:28 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.